Dr. Daryl Hoban
Professor of Medical Microbiology ,University of Manitoba; and Clinical Microbiologist, Health Sciences Centre

Degrees: PhD. (Microbiology)1977, D(ABMM) 1986, FCCM 1988, F(AAM)2006

Mailing Address: Department of Clinical Microbiology, Health Sciences Centre, MS675B-820 Sherbrook Street, Winnipeg, MB R3A 1R9

Tel: (204) 787-1191, Fax: (204) 787-4699, Lab: (204)787-4696
E-mail: dhoban@dsmanitoba.ca

Research Interests:
Molecular basis of antibiotic action. Surveillance of resistant pathogens. Epidemiology of Streptococcus pneumoniae infections.

Recent Publications:

For a list of Dr Hoban's publications, please click here

  1. Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG. Comparison of antimicrobial resistance profiles among extended-spectrum ß-lactamase producing- and acquired AmpC ß-lactamase producing Escherichia coli from Canadian Intensive Care Units. Antimicrobial Agents and Chemotherapy, 2008;52(5):1846-1849.
  2. Lagace-Wiens PRS, DeCorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, the CAN-ICU study group, Zhanel GG. Difference in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables. Canadian Journal of Infectious Disease and Medical Microbiology, 2008;19(4):282-286.
  3. Zhanel GG, DeCorby M. Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagace-Wiens P, Walkty A, Mulvey MR, Hoban DJ, The Canadian Antimicrobial Resistance Alliance (CARA). Diagnostic Microbiology and Infectious Disease, 2008;62:67-80.
  4. Hoban DJ, Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Lagacé-Wiens P, Walkty A, Schweizer F, Adam H, Karlowsky JA, McCracken M, Mulvey MR, Fanella S, Larios O, The Canadian Antimicrobial Resistance Alliance (CARA). Canadian Journal of Infectious Diseases and Medical Microbiology, 2009;20:Suppl A.
  5. Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum ß-lactamases, AmpC ß-lactamases and reduced susceptibility to carbapenems using an in vitro model. Journal of Antimicrobial Chemotherapy, 2009;64:824-828.
  6. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. In vitro activity of Nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrobial Agents and Chemotherapy, 2009;53:4915-4920.
  7. Hawser SP, Bouchillon SK , Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. International Journal of Antimicrobial Agents, 2009;34:585-588.
  8. Adam HJ, Hoban DJ, Gin AS , Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada , 1997-2006. International Journal of Antimicrobial Agents, 2009;34:82-85.
  9. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagnostic Microbiology and Infectious Disease, 2010;66:78-86.
  10. Hawser SP, Hackel M, Hoban DJ. Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenem susceptibility. Journal of Antimicrobial Chemotherapy, 2010:65:803-804.
R&D Laboratory Members:
Laing, Nancy Research Technologist nlaing@hsc.mb.ca 787-4692
Vashisht, Ravinder Research Technologist researchmicro@hsc.mb.ca 787-4696
Weshnoweski, Barb Research Technologist researchmicro@hsc.mb.ca 787-4696